Results for tag: "Sodium Glucose Cotransport 2 Inhibitor"

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of prescription medications used primarily to manage type 2 diabetes mellitus. These medications work by inhibiting the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting excretion of excess glucose through the urine, thereby lowering blood sugar levels. Within the context of endocrine and metabolic disorders drugs, SGLT2 inhibitors represent a modern therapeutic option that extends beyond glucose control, demonstrating potential benefits in reducing the risk of cardiovascular events and the progression of kidney disease in diabetic patients. Additionally, research into the effects of SGLT2 inhibitors has expanded their potential therapeutic use into the treatment of heart failure and chronic kidney disease, even in patients without diabetes. Their role in treating metabolic disorders has highlighted the importance of ongoing research for expanding drug indications and improving patient outcomes. The market for SGLT2 inhibitors encompasses a range of medications that differ in their chemical structure, dosage, and safety profile, and these drugs are often prescribed in conjunction with lifestyle modifications and other antidiabetic agents to optimize glycemic control. Prominent companies in the SGLT2 inhibitor market include AstraZeneca, which markets dapagliflozin; Johnson & Johnson, with canagliflozin; Eli Lilly and Company, in collaboration with Boehringer Ingelheim, offering empagliflozin; and Astellas Pharma, which provides ipragliflozin, primarily Show Less Read more